

Title: Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib

Authors:

Mazyar Shadman, MD, MPH¹, Jeff P. Sharman, MD², Moshe Y. Levy, MD³, Ryan Porter, MD⁴, Syed F. Zafar, MD⁵, John M. Burke, MD⁶, Arvind Chaudhry, MD⁷, Benjamin Freeman, MD⁸, Jamal Misleh, MD⁹, Habte A. Yimer, MD¹⁰, Jennifer L. Cultrera, MD¹¹, Troy H. Guthrie, MD¹², Edwin Kingsley, MD¹³, Subramanya S. Rao, MD¹⁴, Dih-Yih Chen, MD¹⁷, Aileen Cohen MD, PhD¹⁷, Shibo Feng, PhD¹⁷, Jane Huang, MD¹⁷, Ian Flinn, MD, PhD¹⁸; ¹Fred Hutchinson Cancer Research Center,

Author Affiliations:

University of Washington, Seattle, WA; ²Willamette Valley Cancer Institute and Research Center, Eugene, OR; ³Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; ⁴SSM Health Dean Medical Group, Madison, WI; ⁵Florida Cancer Specialists & Research Institute, Fort Myers, FL; ⁶Rocky Mountain Cancer Centers, Aurora, CO; ⁷Summit Cancer Centers, Spokane, WA; ⁸Summit Medical Group, Florham Park, NJ; ⁹Medical Oncology Hematology Consultants PA, Newark, DE; ¹⁰Texas Oncology-Tyler, Tyler, TX; ¹¹Florida Cancer Specialists & Research Institute, Leesburg, FL; ¹²21st Century Oncology, Jacksonville, FL; ¹³Comprehensive Cancer Centers of Nevada, Las Vegas, NV; ¹⁴Alpha Med Physicians Group, Tinley Park, IL; ¹⁷BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA; ¹⁸Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

Background: Many patients (pts) with B-cell malignancies require continuous treatment with Bruton tyrosine kinase inhibitors (BTKi). Adverse events (AEs) are a common reason for ibrutinib (ibr) or acalabrutinib (acala) discontinuation. Early data from BGB-3111-215 showed zanubrutinib (zanu) was well tolerated in pts with B-cell malignancies intolerant to ibr or acala. We report preliminary results with a median follow-up of 4.2 mo.

Methods: Pts meeting protocol criteria for intolerance to ibr, acala or both (without documented progressive disease) were given zanu monotherapy (160 mg twice daily or 320 mg once daily). Recurrence of AEs that led to intolerance of prior BTKi and additional safety measures were assessed based on the Common Terminology Criteria for AEs v5.0. Investigators determined responses using disease status at study entry as baseline.

Results: As of November 1, 2020 (cutoff), 44 pts (n=34 chronic lymphocytic leukemia/small lymphocytic lymphoma, n=6 Waldenström macroglobulinemia, n=2 mantle cell lymphoma, n=2 marginal zone lymphoma) were enrolled, received ≥1 dose of zanu, and analyzed for safety. Median age was 70.5 y (range, 49-91); median duration of treatment was 4.2 mo (range, 0.1-12.6). Median number of prior regimens was 2 (range, 1-12). Regarding prior BTKi, 39 pts received ibr only, 4 received ibr and acala, and 1 received acala only. The median number of ibr- or acala-intolerant AEs per pt was 2 (range, 1-5). 83% of ibr and 78% of acala intolerant events did not recur on zanu; **Table**. At data cutoff, 43 pts remained on treatment; 1 withdrew

consent due to zanu-unrelated grade 3 syncope. Overall, 34 pts (77.3%) reported any AE; most commonly reported AEs were myalgia (n=9; 20.5%), contusion (n=8; 18.2%), dizziness (n=7; 15.9%), fatigue (n=7; 15.9%), and cough (n=5; 11.4%). Grade ≥ 3 AEs were reported in 6 pts (13.6%), serious AEs in 1 pt (2.3%, febrile neutropenia and salmonella infection), AEs requiring dose interruptions in 6 pts (13.6%), and AEs leading to dose reduction in 2 pts (4.5%). No AEs led to zanu discontinuation. No deaths were reported. All efficacy evaluable pts (26/26 [100%]) maintained (10 [38.5%]) or achieved deepening (16 [61.5%]) of their response.

Conclusions: Zanu provides an additional treatment option after intolerance to other BTKi, demonstrating tolerability and sustained or improved efficacy. Updated results will be presented.

Recurrence and Severity Change of AEs Leading to Ibr or Acala Intolerance

	AEs leading to ibr and acala intolerance, N	Recurrence on zanu, n (%)		Severity change of recurrence on zanu, n (%)	
		No	Yes	Recurred at lower severity	Recurred at same severity
Ibr	87	72 (82.8)	15 (17.2)	13 (14.9)	2 (2.3)
Acala	9	7 (77.8)	2 (22.2)	1 (11.1)	1 (11.1)

Note: Multiple events of the same preferred term for a pt are counted once for the event per the worst grade experienced before and after enrollment.